Aurobindo Pharma launches TheraNym, India’s largest biologics CMO

MSD joins as anchor customer as Aurobindo strengthens its position in the fast-growing global biologics manufacturing market

Pfizer and Innovent Biologics strike $10 billion cancer drug deal

This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants

Biopharma firms must diversify CDMO partnerships to avoid costly delays: Shilpa Biologicals MD

Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress

Lonza surges on biologics boom

Expands manufacturing push & locks in major growth deals

ADMA Biologics wins FDA nod to expand ASCENIV use in young children

Biocon Biologics receives 5 procedural observations after US FDA inspection at Bengaluru facility

The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026

JP Nadda highlights India’s push for APIs, biologics and translational research

On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus

Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics

Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies

Aurobindo’s TheraNym to invest up to $175 million in expanded biologics deal with MSD

TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility

Samsung Biologics lands first US manufacturing facility with GSK acquisition

Samsung Biologics will continue supplying products previously manufactured at the site to GSK